An experimental new drug for stiff person syndrome restores mobility
SMRTR summary
A single infusion of an experimental cell therapy called miv-cel dramatically improved mobility in stiff person syndrome patients — a painful autoimmune disease with no FDA-approved treatments. In a 26-person trial, 8 of 12 patients who needed walking aids no longer required them, with one patient progressing from walker-assisted shuffling to running.
SMRTR provides this summary for quick context. The original article belongs to Science News.
Read the original article